UroGen faces earnings test as ZUSDURI launch ramps
#UroGen Pharma #ZUSDURI #Earnings #Q4 2025 #J-Code #Bladder Cancer #Revenue #Profitability #EPS #FDA #Biotech Industry
📌 Key Takeaways
- UroGen Pharma to report Q4 2025 earnings on March 2nd.
- Analysts expect a loss of $0.48 per share on revenue of $41.45 million.
- The earnings report will focus on ZUSDURI's commercial uptake and the impact of its new J-Code.
- Investors will scrutinize revenue mix between ZUSDURI and JELMYTO.
- The company's path to profitability and updated 2026 guidance are key areas of interest.
📖 Full Retelling
UroGen Pharma is reporting its fourth-quarter 2025 earnings on Monday, March 2nd, before the market opens. This report is a critical evaluation of the company's commercial progress following the mid-2025 launch of ZUSDURI, a bladder cancer therapy. Analysts anticipate a loss of $0.48 per share on revenue of $41.45 million, representing sequential improvement from the previous quarter. The focus will be on ZUSDURI’s commercial uptake, specifically whether the new J-Code for the drug has led to increased prescribing. Investors will also analyze the revenue mix between ZUSDURI and JELMYTO, and the company's path to profitability.
🏷️ Themes
Biotech, Earnings Report, Commercialization, Drug Launch, Financial Performance, Healthcare, Bladder Cancer
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Middle East tensions rise as Iran promises retaliation $100+ oil back in play if Hormuz disruption worsens: analysts Wait for a 10% drop in the S&P 500 before buying the dip, Barclays says U.S. dollar seen strengthening as U.S.-Israel strikes intensify (South Africa Philippines Nigeria) UroGen faces earnings test as ZUSDURI launch ramps By Investing.com Earnings Published 03/01/2026, 09:35 AM UroGen faces earnings test as ZUSDURI launch ramps 0 URGN 2.46% UroGen Pharma is set to report fourth-quarter 2025 results on Monday, March 2nd, before the market opens, in what marks a critical test of the biotech’s commercial transformation following the mid-2025 launch of its bladder cancer therapy ZUSDURI. Analysts expect the company to post a loss of $0.48 per share on revenue of $41.45 million for the quarter. If realized, that would represent substantial sequential improvement from the third quarter, when UroGen reported a loss of $0.69 per share on revenue of $27.48 million that fell short of expectations. Year-over-year, the consensus implies EPS improving by nearly 40% and revenue surging 69%. Yet enthusiasm has been tempered in recent weeks. EPS estimates have declined 4.68% over the past 60 days, while revenue estimates have slipped 3.69% over the same period, though both have held steady over the past week. Despite the pullback, analysts remain bullish on the stock, with seven of eight rating it a Buy and a consensus price target of $35.25—implying 62% upside from the current $21.18 share price. What Investors Are Watching The primary focus will be on ZUSDURI’s commercial uptake. The permanent J-Code for ZUSDURI became effective January 1, 2026, and is expected to streamline billing and reimbursement processes, reducing administrative delays. Investors will scrutinize whether the coding change translated into accelerated prescribing in late Q4 and early 2026, and listen for management’s guidance on the launc...
Read full article at source